DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Retrobulbar Triamcinolone Acetonide Injection in the Treatment of NA-AION

Information source: Second Military Medical University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Triamcinolone Acetonide; Optic Neuropathy, Ischemic

Intervention: Triamcinolone Acetonide (Drug); placebo (Drug)

Phase: Phase 3

Status: Not yet recruiting

Sponsored by: Second Military Medical University

Official(s) and/or principal investigator(s):
shihong zhao, Study Director, Affiliation: department of ophthalmology

Overall contact:
DONGYAN PAN, Dr, Phone: 86-21-31161995, Email: campus@126.com

Summary

NAION produces an ischemic insult in the optic nerve head presumably due to the hypoperfusion of the short ciliary arteries that supply it. Intravenous injection of glucocorticoid have proven to be effective in treatment of Nonarteritic Anterior Ischemic Optic Neuropathy,but have some side effects. the investigators believe that offering them Retrobulbar Triamcinolone Acetonide Injection that might halt the progression of the visual acuity and visual field loss if our hypothesis is correct, would greatly improve their chances of avoiding blindness.

Clinical Details

Official title: Retrobulbar Triamcinolone Acetonide Injection in the Treatment of Nonarteritic Anterior Ischemic Optic Neuropathy

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Changes of Best corrected visual acuity(BCVA)

Secondary outcome: Changes of Visual Field

Eligibility

Minimum age: 18 Years. Maximum age: 80 Years. Gender(s): Both.

Criteria:

Inclusion Criteria: Sudden mono ocular vision loss associated with optic disc edema and positive Marcus Gunn (<30 days) Exclusion Criteria: Any eye disease except NAION(Nonarteritic Anterior Ischemic Optic Neuropathy) Neurologic defect Abnormal ESR, CRP, any history of retina or vitreal surgery Severe corneal opacity which makes retina examination impossible

Locations and Contacts

DONGYAN PAN, Dr, Phone: 86-21-31161995, Email: campus@126.com

Additional Information

Starting date: May 2015
Last updated: March 27, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017